Tag Archives: NVCR

Best Performing Stocks For 2021

Why is the dollar so weak even as Treasury yields are on the rise? Some economists argue that the blame lies with the twins.

No, not the starkly contrasting, fraternal twins who were separated at birth in the 1988 film Twins, featuring Arnold Schwarzenegger and Danny DeVito.

Rather the additional fiscal boost to the U.S. economy coming from the tax cuts signed into law late last year by President Donald Trump and a two-year budget deal, which are expected to deepen the budget deficit and the current-account deficita combo termed the twin deficits.

Best Performing Stocks For 2021: STERIS Corporation(STE)

STERIS Corporation and its subsidiaries develop, manufacture, and sell infection prevention, contamination control, microbial reduction, and surgical support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. It provides steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers; liquid chemical sterilant processing systems; washer/disinfector systems; general and specialty surgical tables; surgical and examination lights; equipment management systems; operating room storage cabinets; warming cabinets; scrub sinks; and other products and accessories. The company also offers connectivity solutions, such as operating room integration, workflow, patient tracking, and instrument management that allow transfer of information and images; cleaning chemistries and sterility assurance products; cleansing products, including hard surface disinfectants, and skin care and hand hygiene solutions; high-pu rity water equipment; vaporized hydrogen peroxide generators. In addition, it sells contract materials processing services using gamma irradiation and ethylene oxide technologies, as well as offers microbial reduction services based on customer specifications. Further, the company provides maintenance programs and repair services, sterilization and surgical management consulting services, information management and decision support services, and other support services, such as construction and facility planning, engineering support, device testing, customer education, hand hygiene process excellence, asset management/planning, and the sale of replacement parts. STERIS Corporation sells its products to end users, dealers, and distributors through direct field sales and service representatives. The company was formerly known as Innovative Medical Technologies and changed its name to STERIS Corporation in 1987. STERIS Corporation was founded in 1985 and is headquartered in Ment or, Ohio.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Steris Corp (NYSE:STE)Q32019 Earnings Conference CallFeb. 12, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Stephan Byrd]

    Shares of Steris PLC (NYSE:STE) have received a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $98.00.

  • [By Stephan Byrd]

    Shares of Steris PLC (NYSE:STE) have been given an average recommendation of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $98.00.

Best Performing Stocks For 2021: Blackrock Health Sciences Trust(BME)

BlackRock Health Sciences Trust (the Trust) is a non-diversified, closed-end management investment company. The Trusts investment objective is to provide total return through a combination of current income and capital appreciation. BlackRock Health Sciences Trust seeks to achieve this objective by investing primarily in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. Trust will invest at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry.

BlackRock Health Sciences Trust invests in various sectors, which include pharmaceuticals, healthcare products, biotechnology, healthcare services, electronics, retail and distribution/wholesale. It operates in countries, such as United States, Switzerland, China, France, Germany, Canada and United Kingdom.

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of BME traded up $0.60 during midday trading on Monday, hitting $40.92. The company had a trading volume of 34,700 shares, compared to its average volume of 35,130. Blackrock Health Sciences Trust has a 52 week low of $32.00 and a 52 week high of $44.00.

    TRADEMARK VIOLATION WARNING: “Blackrock Health Sciences Trust Declares Monthly Dividend of $0.20 (BME)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at www.tickerreport.com/banking-finance/4125742/blackrock-health-sciences-trust-declares-monthly-dividend-of-0-20-bme.html.

    About Blackrock Health Sciences Trust

  • [By Logan Wallace]

    Shares of B&M European Value Retail SA (LON:BME) have been assigned an average recommendation of “Buy” from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 451.36 ($5.88).

  • [By Max Byerly]

    B&M European Value Retail (LON:BME) had its target price boosted by analysts at HSBC from GBX 470 ($6.26) to GBX 500 ($6.66) in a report released on Wednesday. The brokerage presently has a “buy” rating on the stock. HSBC’s price objective indicates a potential upside of 21.54% from the company’s current price.

Best Performing Stocks For 2021: NovoCure Limited(NVCR)

NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.

Advisors’ Opinion:

  • [By Brian Feroldi]

    Medical device makers were some of the best-performing companies on the market last year. In this week’s episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Brian Feroldi talk about three medical device monopolies that investors might want to take a closer look at. Listen and find out what makes Intuitive Surgical(NASDAQ:ISRG), Abiomed(NASDAQ:ABMD), and NovoCure (NASDAQ:NVCR)stand out from the crowd, dominate their niches, and improve patient lives. Plus, learn the key metrics investors should watch, what long-term risks to be aware of, which of the companies faces the most competitive risk, some of the most exciting opportunities still ahead, and more.

  • [By Ethan Ryder]

    Novocure (NASDAQ:NVCR) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

  • [By Beth McKenna]

    Novocure Ltd. (NASDAQ:NVCR) stock jumped 16.3% in September, according to data fromS&P Global Market Intelligence. For context, theS&P 500 returned0.6% last month.

Best Performing Stocks For 2021: Express Scripts Holding Company(ESRX)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe. The company operates through two segments, PBM and Other Business Operations. The companys PBM segments products and services include clinical solutions to enhance health outcomes; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services, including design, implementation, and project management for pharmaceutical, biotechnology, and device manufacturers to collect scientific evidence to guide the use of medicines. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2015, the company operated four automated dispensing home delivery pharmacies; one non-automated dispensing home delivery pharmacy; and one non-dispensing home delivery pharmacy maintained for business continuity purpose, as well as several non-dispensing order processing centers, patient contact centers, specialty drug pharmacies, and fertility pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

Advisors’ Opinion:

  • [By Shane Hupp]

    Bank of Stockton raised its holdings in Express Scripts Holding Co (NASDAQ:ESRX) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,821 shares of the company’s stock after buying an additional 581 shares during the period. Bank of Stockton’s holdings in Express Scripts were worth $1,123,000 as of its most recent SEC filing.

  • [By Brian Orelli]

    Discounts off the list price vary widely from disease to disease, but they’re largely tied to how many competitors there are in the space. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE:ABBV), which sells Mavyret and Viekira Pak, they can get steeper discounts than if there’s only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation, PBM Express Scripts (NASDAQ:ESRX) was only covering AbbVie’s drug for a while, and Express Scripts has removed drugs in other diseases from its formulary for playing hardball on negotiations.

  • [By Todd Campbell]

    Its lackluster launch isn’t a secret, though, and now that its cardiovascular outcomes study has shown it lowers the risk of cardiovascular events including heart attack, stroke, and death, its sales are beginning to perk up. The FDA hasn’t approved adding the outcomes data to Praluent’s prescribing label yet (a decision is expected next April), but that hasn’t stopped doctors from prescribing it more frequently, or payers from dropping barriers to its access. In Q2, Praluent’s revenue was $73.5 million, a nearly $300 million annualized sales run rate, up from $46.1 million in the same quarter last year. Importantly, a deal with the nation’s second-largest pharmacy benefit manager, Express Scripts (NASDAQ:ESRX), makes it the preferred drug in its class for Express Scripts patients beginning in July, and that should provide a nice sales boost from here.

  • [By Demitrios Kalogeropoulos]

    Express Scripts Holding Company (NASDAQ:ESRX) outpaced the market by gaining 11% last month compared to a 3% jump in the S&P 500, according to data provided by S&P Global Market Intelligence.

Best Clean Energy Stocks To Invest In Right Now

Rational Advisors LLC boosted its holdings in shares of Viacom, Inc. Class B (NASDAQ:VIAB) by 95,431.8% during the 2nd quarter, Holdings Channel reports. The firm owned 21,017 shares of the company’s stock after purchasing an additional 20,995 shares during the period. Rational Advisors LLC’s holdings in Viacom, Inc. Class B were worth $634,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of VIAB. Mount Yale Investment Advisors LLC purchased a new position in Viacom, Inc. Class B during the 1st quarter worth $126,000. Financial Gravity Wealth Inc. purchased a new position in Viacom, Inc. Class B during the 1st quarter worth $197,000. Greenleaf Trust purchased a new position in Viacom, Inc. Class B during the 1st quarter worth $237,000. Campbell & CO Investment Adviser LLC purchased a new position in Viacom, Inc. Class B during the 1st quarter worth $238,000. Finally, Intact Investment Management Inc. purchased a new position in Viacom, Inc. Class B during the 2nd quarter worth $238,000. 77.55% of the stock is currently owned by institutional investors.

Best Clean Energy Stocks To Invest In Right Now: ResMed Inc.(RMD)

ResMed Inc., incorporated on March 31, 1994, is a holding company. The Company, through its subsidiaries, designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Company develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories.

The Company owns interest in Inova Labs, Inc., a medical device company specializing in the development and commercialization of oxygen therapy products. The Company holds interest in Brightree LLC, a provider of business management and clinical software applications for the post-acute care industry. The Company’s manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Next, two years ago, he picked “Five Stocks for April the Giraffe,” the Washington Zoo favorite who was live-streamed giving birth to baby Tajiri. Those were Axon Enterprise (NASDAQ:AAXN), Grupo Aeroportuario del Pacífico (NYSE:PAC), ResMed  (NYSE:RMD), Intuitive Surgical, and Live Nation (NYSE:LYV). The first letters of their tickers spell out A-P-R-I-L, and David and senior analyst Brian Feroldi will let us know if their returns should put a spring in your step. 

  • [By Joseph Griffin]

    In related news, insider Robert Andrew Douglas sold 4,193 shares of the business’s stock in a transaction on Monday, December 17th. The stock was sold at an average price of $112.56, for a total value of $471,964.08. Following the completion of the sale, the insider now directly owns 89,605 shares in the company, valued at approximately $10,085,938.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Hollingshead sold 5,893 shares of the business’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $105.52, for a total value of $621,829.36. Following the completion of the sale, the insider now owns 75,121 shares of the company’s stock, valued at $7,926,767.92. The disclosure for this sale can be found here. Insiders sold a total of 53,633 shares of company stock valued at $5,728,098 over the last 90 days. 1.24% of the stock is currently owned by corporate insiders.

    TRADEMARK VIOLATION NOTICE: “ResMed Inc. (RMD) Holdings Decreased by Canandaigua National Bank & Trust Co.” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at www.tickerreport.com/banking-finance/4153639/resmed-inc-rmd-holdings-decreased-by-canandaigua-national-bank-trust-co.html.

    ResMed Company Profile

Best Clean Energy Stocks To Invest In Right Now: CVS Health Corporation(CVS)

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, managed Medicaid plans and plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS Pharmacy, CVS Specialty, Accordant, SilverScript, NovoLogix, Coram, Navarro Health Services, and Advanced Care Scripts names. As of December 31, 2015, it operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies and 5 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail/LTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as provides photo finishing services. It operates 9,655 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 32 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

Advisors’ Opinion:

  • [By Chris Hill]

    In this episode of Motley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Disney (NYSE:DIS) finishes up its merger with Fox, and it’s ready to take on a crowded streaming space. CVS Health (NYSE:CVS) diversifies into CBD lotion. Levi Strauss (NYSE:LEVI) enters the public markets with a bafflingly high market cap, while Nike (NYSE:NKE) sells off on higher-than-expected revenue and profits. Biogen’s (NASDAQ:BIIB) biggest trial bombs, and the stock tanks along with it. Papa John’s (NASDAQ:PZZA) welcomes Shaq into its board of directors. And, as always, the analysts share some stocks on their radar. Plus, stay tuned for an interview with Lake House Capital’s Joe Magyer about investing in Australia — the biggest trends, biggest worries, and some Aussie picks to add to your watch list.

  • [By Jeremy Bowman]

    Shares of CVS (NYSE:CVS) were slipping in February after the drugstore chain signaled that its performance in 2019 would be challenged as it absorbed its nearly $70 billion acquisition of Aetna, the health insurance giant. That news weighed on fourth-quarter results, and the stock finished the month down 12%, according to data from S&P Global Market Intelligence.

  • [By Joseph Griffin]

    ILLEGAL ACTIVITY NOTICE: “CVS Health Corp (CVS) Shares Bought by St. Johns Investment Management Company LLC” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at www.tickerreport.com/banking-finance/4196785/cvs-health-corp-cvs-shares-bought-by-st-johns-investment-management-company-llc.html.

  • [By Motley Fool Staff]

    CVS (NYSE:CVS) has a deal in place to acquire Aetna. That will transform the company but it has yet to receive final regulatory approval. Whether that deal gets approved has cast a shadow over its 2019 prospects. That’s largely because the deal marks a major change for the company as it moves into a new space — insurance — that’s a changing market.

Best Clean Energy Stocks To Invest In Right Now: Aimia Inc. (GAPFF)

Aimia Inc. is a Canada-based data-driven marketing and loyalty analytics company. The Company, through its subsidiaries, operates in the regional business segments of Canada; the United States and Asia-Pacific (US & APAC), and Europe, the Middle-East and Africa (EMEA). In Canada, it owns and operates the Aeroplan Program, a coalition loyalty program. In EMEA, it owns and operates coalition loyalty programs, including Nectar UK and Air Miles Middle East, through over 60% ownership interest. Its EMEA segment also provides data-driven analytics and insights services in the United Kingdom and internationally to retailers and their suppliers. In addition, it develops analytical tools to provide services to clients globally to collect, analyze and derive actionable insight from their customer data. In each of the regions, it provides loyalty services, including loyalty program strategy, design, launch and operation of platforms, including Aimia Loyalty Platform and Smart Button. Advisors’ Opinion:

  • [By ]

    The preferred shares for Aimia (OTCPK:GAPFF) offer an attractive investment return of 28%, assuming redemption, in contrast to the common shares which are trading at their fair value. We believe the market is under-pricing the preferred shares.

  • [By SEEKINGALPHA.COM]

    Aimia (OTCPK:GAPFF) (TSX: AIM, AIM.PR.A, AIM.PR.B, AIM.PR.C)

    As some background, we are intimately familiar with Aeroplan and Air Canada (OTCQX:ACDVF) not just as investors but as extraordinarily heavy consumers. As both an Air Canada top tier elite and Aeroplan top tier member I generate well in excess of 1.5 million Aeroplan miles annually, half from flying Air Canada and its partners and the other half from spending. As consumers we were concerned with Air Canada’s decision (though we expect more details to come out that will alleviate these concerns) but as investors we understand that the fundamental business model of mileage programs are incredibly attractive and that Aimia presents an incredibly rare and lucrative investment opportunity for the investor discerning enough to dig into the company.

Best Clean Energy Stocks To Invest In Right Now: InterOil Corporation(IOC)

InterOil Corporation (InterOil), incorporated on August 24, 2007, is an oil and gas business with a sole focus on Papua New Guinea (PNG). The Company’s segments include Upstream and Corporate. The Upstream segment includes exploration, appraisal and development of hydrocarbon structures in PNG. The Corporate segment provides support to the Company’s other business segments through business development and improvement activities, general services, administration, human resources, executive management, financing and treasury, government affairs and investor relations.

The Company holds interests across over four exploration and approximately two production retention licenses in the Eastern Papuan Basin of Papua New Guinea. InterOil’s assets include the Elk, Antelope, Triceratops, Raptor and Bobcat fields in the Gulf Province of Papua New Guinea, and exploration licenses covering approximately 16,000 square kilometers (over four million acres) in Papua New Guinea. Papua LNG is PNG’s liquefied natural gas (LNG) project and is supported by the Elk-Antelope gas field, located in the Eastern Papuan Basin. The subsidiaries of InterOil include SPI Exploration and Production Corporation, InterOil Singapore Pte Ltd, InterOil Corporate PNG Limited, South Pacific Refining Limited, SPI Distribution Limited, InterOil LNG Holdings Inc., InterOil Australia Pty Ltd, InterOil Finance Inc., InterOil Shipping Pte Ltd and their subsidiaries.

Advisors’ Opinion:

  • [By Shane Hupp]

    I/O Coin (CURRENCY:IOC) traded 26.1% higher against the US dollar during the one day period ending at 22:00 PM E.T. on August 17th. Over the last seven days, I/O Coin has traded up 50% against the US dollar. One I/O Coin coin can now be purchased for $0.39 or 0.00005901 BTC on exchanges. I/O Coin has a market capitalization of $6.55 million and approximately $14,268.00 worth of I/O Coin was traded on exchanges in the last day.

  • [By Stephan Byrd]

    Media headlines about InterOil (NYSE:IOC) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. InterOil earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news articles about the oil and gas company an impact score of 45.5148763796823 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Best Clean Energy Stocks To Invest In Right Now: TESARO, Inc.(TSRO)

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which has completed phase 3 oral formulation trials, as well as is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that is in phase 3 clinical trials to treat ovarian cancer; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA, a programmed cell death protein 1 antibody for the treatment of certain melanomas. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    TESARO Inc (NASDAQ:TSRO) – Equities researchers at Leerink Swann issued their Q3 2018 EPS estimates for TESARO in a report issued on Monday, September 24th. Leerink Swann analyst A. Berens anticipates that the biopharmaceutical company will post earnings per share of ($2.77) for the quarter. Leerink Swann has a “Outperform” rating and a $48.00 price target on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2018 earnings at ($2.77) EPS, FY2018 earnings at ($11.55) EPS, FY2019 earnings at ($8.53) EPS and FY2020 earnings at ($3.58) EPS.

  • [By Todd Campbell]

    If Opko Health escapes unscathed by the SEC, then investors’ attention will return to the company’s prospects. Unfortunately, the company’s performance lately has been lackluster. Partner Tesaro (NASDAQ:TSRO) walked away from Opko’s chemotherapy-induced nausea and vomiting drug, Varubi, earlier this year following concerns over safety. Meanwhile, sales of Opko’s hyperparathyroidism treatment, Rayaldee, have been anemic. Despite winning FDA approval in 2016, Rayaldee only had $4.8 million in sales in the second quarter of 2018. The company’s lab business has also seen sales slip. Altogether, Opko Health’s revenue declined 10% to $263.7 million last quarter.

  • [By Logan Wallace]

    Tocqueville Asset Management L.P. lessened its holdings in TESARO Inc (NASDAQ:TSRO) by 91.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,415 shares of the biopharmaceutical company’s stock after selling 69,700 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in TESARO were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Todd Campbell]

    If that’s the case, then Opko Health is going to need some big wins. Unfortunately, Opko Health’s acquisitions haven’t panned out so far. It’s been slow going for Rayaldee, and BioReference Labs’ revenue is declining. Also, a chemotherapy-induced nausea and vomiting drug, Varubi, that it licensed to Tesaro (NASDAQ:TSRO) and that won FDA approval in 2015 has been a commercial dud. Earlier this year, Tesaro walked away from Varubi after it had to pull an IV formulation off the market following reports of anaphylaxis. Overall, Opko reported a $6.2 million net loss on $263.7 million in sales, down 10% year over year, in Q2. 

Best Clean Energy Stocks To Invest In Right Now: NovoCure Limited(NVCR)

NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.

Advisors’ Opinion:

  • [By Brian Feroldi]

    Medical device makers were some of the best-performing companies on the market last year. In this week’s episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Brian Feroldi talk about three medical device monopolies that investors might want to take a closer look at. Listen and find out what makes Intuitive Surgical (NASDAQ:ISRG), Abiomed (NASDAQ:ABMD), and NovoCure (NASDAQ:NVCR) stand out from the crowd, dominate their niches, and improve patient lives. Plus, learn the key metrics investors should watch, what long-term risks to be aware of, which of the companies faces the most competitive risk, some of the most exciting opportunities still ahead, and more.

  • [By Ethan Ryder]

    Novocure (NASDAQ:NVCR) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

  • [By Beth McKenna]

    Novocure Ltd. (NASDAQ:NVCR) stock jumped 16.3% in September, according to data from S&P Global Market Intelligence. For context, the S&P 500 returned 0.6% last month.

  • [By Joseph Griffin]

    Schwab Charles Investment Management Inc. increased its position in Novocure Ltd (NASDAQ:NVCR) by 30.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 133,900 shares of the medical equipment provider’s stock after buying an additional 31,300 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.14% of Novocure worth $4,192,000 as of its most recent filing with the Securities and Exchange Commission.